Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 1, 2006Annals of Pharmacotherapy

Sitagliptin is a potent DPP-IV inhibitor that is effective as monotherapy or adjunctive therapy for type 2 diabetes, without causing weight gain or hypoglycemia.

View Full Paper
Ask AI
Bookmark
Share

Why the study?

Is sitagliptin effective and safe for the management of type 2 diabetes mellitus?

Population

Patients with type 2 diabetes mellitus

Comparison

Sitagliptin as monotherapy or adjunctive therapy vs Placebo or active comparators (e.g., glipizide)

Design

Review

Key result

Sitagliptin is a potent DPP-IV inhibitor that is effective as monotherapy or adjunctive therapy for type 2 diabetes, without causing weight gain or hypoglycemia.

Authors

SMShannon MillerEOErin St. Onge

Discussion

Loading...

Member takes

Overview

Sitagliptin offers a novel oral incretin option for type 2 diabetes; leaves open long-term outcomes and durability.

Structured PICO

Is sitagliptin effective and safe for the management of type 2 diabetes mellitus?

P
Population
Patients with type 2 diabetes mellitus
I
Intervention
Sitagliptin (dipeptidyl peptidase IV inhibitor) as monotherapy or adjunctive therapy
C
Comparator
Placebo or active comparators (e.g., glipizide)
O
Outcome
Efficacy and safety in the management of type 2 diabetes mellitus

Sitagliptin is an effective and safe treatment option for type 2 diabetes, both as monotherapy and adjunctive therapy, without causing weight gain or hypoglycemia.

Cite This Study

Miller et al. (2006) conducted a review in Type 2 diabetes mellitus. Sitagliptin vs. Placebo, glipizide, metformin, sulfonylureas was evaluated. Sitagliptin is a potent DPP-IV inhibitor that is effective as monotherapy or adjunctive therapy for type 2 diabetes, without causing weight gain or hypoglycemia.

synapsesocial.com/papers/6a6bcb1b47a1bfb288f347ffhttps://doi.org/10.1345/aph.1g665
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Sitagliptin is a time-tested leading drug in the treatment of type 2 diabetes2024
  2. 2Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin2007 · 526 citations
  3. 3Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin on Atherosclerosis, β-Cell Function, and Glycemic Control in Japanese Patients with Type 2 Diabetes Mellitus Who are Treatment Naïve or Poorly Responsive to Antidiabetes Agents: A Multicenter, Prospective Observational, Uncontrolled Study2017 · 12 citations
  4. 4Exploring the Clinical Pharmacokinetics of Sitagliptin in Healthy and Diseased Populations: A Systematic Critical Review2026
  5. 5Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial2007 · 669 citations